{"id":"https://openalex.org/W4391745346","doi":"https://doi.org/10.1002/cpdd.1379","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults","display_name":"Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults","alternate_titles":[],"publication_year":2024,"publication_date":"2024-02-12","ids":{"openalex":"https://openalex.org/W4391745346","doi":"https://doi.org/10.1002/cpdd.1379","pmid":"https://pubmed.ncbi.nlm.nih.gov/38345530"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.1379","doi":"https://doi.org/10.1002/cpdd.1379","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1379","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1379","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4391745346"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1379","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061422874","display_name":"Caroline A. Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Caroline A. Lee","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059435501","display_name":"Stefan Schreiber","orcid":"https://orcid.org/0000-0003-2254-7771","observed_orcids":["https://orcid.org/0000-0003-2254-7771"]},"institutions":[{"id":"https://openalex.org/I32021983","display_name":"Christian-Albrechts-Universit\u00e4t zu Kiel","ror":"https://ror.org/04v76ef78","country_code":"DE","type":"education","lineage":["https://openalex.org/I32021983"]},{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stefan Schreiber","raw_affiliation_strings":["Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany","Excellence Cluster Precision Medicine in Inflammation, Christian-Albrecht University of Kiel, Kiel, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany","institution_ids":["https://openalex.org/I4210112713"]},{"raw_affiliation_string":"Excellence Cluster Precision Medicine in Inflammation, Christian-Albrecht University of Kiel, Kiel, Germany","institution_ids":["https://openalex.org/I32021983"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062818239","display_name":"Brian L. Bressler","orcid":"https://orcid.org/0000-0003-4740-8209","observed_orcids":["https://orcid.org/0000-0003-4740-8209"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]},{"id":"https://openalex.org/I2801362399","display_name":"St. Paul's Hospital","ror":"https://ror.org/00wzdr059","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801362399"]}],"countries":["CA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brian Bressler","raw_affiliation_strings":["Department of Medicine, Division of Gastroenterology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Gastroenterology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada","institution_ids":["https://openalex.org/I141945490","https://openalex.org/I2801362399"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057331430","display_name":"John W. Adams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John W. Adams","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110468453","display_name":"D. Alexander Oh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dooman Alexander Oh","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086917542","display_name":"Yong Q. Tang","orcid":"https://orcid.org/0000-0002-0159-2242","observed_orcids":["https://orcid.org/0000-0002-0159-2242"]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yong Q. Tang","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103045702","display_name":"Jinkun Zhang","orcid":"https://orcid.org/0009-0002-1870-9125","observed_orcids":["https://orcid.org/0009-0002-1870-9125"]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jinkun Zhang","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113436005","display_name":"Heather Kiyomi Komori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Heather Kiyomi Komori","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006693033","display_name":"John S. Grundy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126734","display_name":"Arena Pharmaceuticals (United States)","ror":"https://ror.org/02w3y1050","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126734"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John S. Grundy","raw_affiliation_strings":["Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","At the time of this analysis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210126734"]},{"raw_affiliation_string":"At the time of this analysis","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5061422874"],"corresponding_institution_ids":["https://openalex.org/I4210126734"],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":{"value":3620,"currency":"USD","value_usd":3620},"fwci":2.2318,"has_fulltext":true,"cited_by_count":23,"citation_normalized_percentile":{"value":0.89643158,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"13","issue":"5","first_page":"534","last_page":"548"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.9491999745368958,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.9491999745368958,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.012000000104308128,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/etrasimod","display_name":"etrasimod","score":1.0},{"id":"https://openalex.org/keywords/sphingosine-1-phosphate-receptor-modulator","display_name":"sphingosine-1-phosphate receptor modulator","score":0.9480000138282776},{"id":"https://openalex.org/keywords/immune-mediated-inflammatory-diseases","display_name":"immune-mediated inflammatory diseases","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9380000233650208},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.7260000109672546},{"id":"https://openalex.org/keywords/lymphocyte-reduction","display_name":"lymphocyte reduction","score":0.5590000152587891},{"id":"https://openalex.org/keywords/heart-rate-reduction","display_name":"heart rate reduction","score":0.7149999737739563},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7950000166893005},{"id":"https://openalex.org/keywords/oral-clearance","display_name":"oral clearance","score":0.6740000247955322},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8630096912384033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8568993806838989},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.839964747428894},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7694944143295288},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5786997675895691},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5716066360473633},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5360128879547119},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38598811626434326},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.336401104927063}],"mesh":[{"descriptor_ui":"D000081025","descriptor_name":"Sphingosine-1-Phosphate Receptors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000081243","descriptor_name":"Sphingosine 1 Phosphate Receptor Modulators","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000081243","descriptor_name":"Sphingosine 1 Phosphate Receptor Modulators","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000081243","descriptor_name":"Sphingosine 1 Phosphate Receptor Modulators","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000081243","descriptor_name":"Sphingosine 1 Phosphate Receptor Modulators","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpdd.1379","doi":"https://doi.org/10.1002/cpdd.1379","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1379","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1379","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:38345530","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38345530","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/cpdd.1379","doi":"https://doi.org/10.1002/cpdd.1379","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1379","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1379","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4391745346.pdf","grobid_xml":"https://content.openalex.org/works/W4391745346.grobid-xml"},"referenced_works_count":58,"referenced_works":["https://openalex.org/W132678722","https://openalex.org/W138217808","https://openalex.org/W1493585689","https://openalex.org/W1494056289","https://openalex.org/W1549006420","https://openalex.org/W1604550075","https://openalex.org/W1723112598","https://openalex.org/W1973354423","https://openalex.org/W1974151956","https://openalex.org/W2006985918","https://openalex.org/W2009504760","https://openalex.org/W2025402613","https://openalex.org/W2035289421","https://openalex.org/W2038934774","https://openalex.org/W2040300892","https://openalex.org/W2043201276","https://openalex.org/W2047601088","https://openalex.org/W2068019570","https://openalex.org/W2075826741","https://openalex.org/W2078067317","https://openalex.org/W2095707498","https://openalex.org/W2097319089","https://openalex.org/W2100041813","https://openalex.org/W2103341573","https://openalex.org/W2118735809","https://openalex.org/W2149070466","https://openalex.org/W2151015747","https://openalex.org/W2151340435","https://openalex.org/W2152730481","https://openalex.org/W2157586986","https://openalex.org/W2161227647","https://openalex.org/W2496806206","https://openalex.org/W2508930552","https://openalex.org/W2529362670","https://openalex.org/W2593267944","https://openalex.org/W2606433496","https://openalex.org/W2752721387","https://openalex.org/W2754752946","https://openalex.org/W2788933778","https://openalex.org/W2792921896","https://openalex.org/W2899411597","https://openalex.org/W2900859423","https://openalex.org/W2920826112","https://openalex.org/W2920941213","https://openalex.org/W2943418595","https://openalex.org/W2949971221","https://openalex.org/W2954577975","https://openalex.org/W2958757303","https://openalex.org/W2976975088","https://openalex.org/W2984675782","https://openalex.org/W3004409654","https://openalex.org/W3022909655","https://openalex.org/W3125808780","https://openalex.org/W3162784420","https://openalex.org/W3189274587","https://openalex.org/W3202460246","https://openalex.org/W4322762554","https://openalex.org/W4367834272"],"related_works":["https://openalex.org/W2791816688","https://openalex.org/W2586099691","https://openalex.org/W4410964673","https://openalex.org/W2586904892","https://openalex.org/W2999107720","https://openalex.org/W3110704221","https://openalex.org/W3208707334","https://openalex.org/W3169012642","https://openalex.org/W2920826112","https://openalex.org/W1604550075"],"abstract_inverted_index":{"Etrasimod":[0,144],"is":[1],"an":[2],"investigational,":[3],"once-daily,":[4],"oral,":[5],"selective":[6],"sphingosine":[7],"1-phosphate":[8],"receptor":[9],"1,4,5":[10],"modulator":[11],"in":[12,148,152,213],"development":[13,218],"for":[14,223],"immune-mediated":[15],"inflammatory":[16],"diseases":[17],"(IMIDs).":[18],"Here,":[19],"we":[20],"report":[21],"the":[22,65,88,94,193],"human":[23],"safety,":[24,206],"pharmacokinetics,":[25],"and":[26,41,70,97,101,116,126,141,208,219],"pharmacodynamics":[27],"of":[28,196,211,225],"etrasimod":[29,104,113,139,183,212],"obtained":[30],"from":[31,121,150,157,179],"both":[32],"a":[33,42],"single":[34,69,140],"ascending":[35,44],"dose":[36,45,195],"(SAD;":[37],"0.1-5":[38],"mg)":[39],"study":[40],"multiple":[43,71,142,145],"(MAD;":[46],"0.35-3":[47],"mg":[48,79,202],"once":[49],"daily)":[50],"study.":[51],"Overall,":[52],"99":[53],"healthy":[54],"volunteers":[55],"(SAD":[56],"n":[57,61],"=":[58,62],"40,":[59],"MAD":[60],"59)":[63],"completed":[64],"2":[66],"studies.":[67],"Evaluated":[68],"doses":[72],"were":[73,87,107],"well":[74],"tolerated":[75],"up":[76,197],"to":[77,123,128,159,167,198],"3":[78],"without":[80],"severe":[81],"adverse":[82],"events":[83],"(AEs).":[84],"Gastrointestinal":[85],"disorders":[86],"most":[89],"common":[90],"etrasimod-related":[91],"AEs.":[92],"Over":[93],"evaluated":[95],"single-":[96],"multiple-dose":[98],"ranges,":[99],"dose-proportional":[100],"marginally":[102],"greater-than-dose-proportional":[103],"plasma":[105],"exposure":[106],"observed,":[108],"respectively.":[109,131],"At":[110],"steady":[111],"state,":[112],"oral":[114],"clearance":[115],"half-life":[117],"mean":[118,189],"values":[119],"ranged":[120],"1.0":[122],"1.2":[124],"L/h":[125],"29.7":[127],"36.4":[129],"hours,":[130],"Dose-dependent":[132],"total":[133,153],"peripheral":[134],"lymphocyte":[135,154],"reductions":[136,149,190],"occurred":[137],"following":[138,173],"dosing.":[143],"dosing":[146,184],"resulted":[147],"baseline":[151,181],"counts":[155,165],"ranging":[156],"41.1%":[158],"68.8%":[160],"after":[161,192],"21":[162],"days.":[163],"Lymphocyte":[164],"returned":[166],"normal":[168],"range":[169],"within":[170],"7":[171],"days":[172],"treatment":[174,224],"discontinuation.":[175],"Heart":[176],"rate":[177],"lowering":[178],"pretreatment":[180],"on":[182],"was":[185],"typically":[186],"mild,":[187],"with":[188],"seen":[191],"first":[194],"19.5":[199],"bpm":[200],"(5":[201],"dose).":[203],"The":[204],"favorable":[205],"pharmacokinetic,":[207],"pharmacodynamic":[209],"properties":[210],"humans":[214],"supported":[215],"its":[216,221],"further":[217],"warranted":[220],"investigation":[222],"IMIDs.":[226]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4391745346","counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2024-02-13T00:00:00"}
